Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis
Primary Purpose
End Stage Renal Disease
Status
Unknown status
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
omega-3
empty soft gelatin capsules
Sponsored by
About this trial
This is an interventional treatment trial for End Stage Renal Disease focused on measuring omega-3 fatty acids, hemodialysis, oxidative stress, dyslipidemia
Eligibility Criteria
Inclusion Criteria:
- Patients between 8 and 18 years old
- Patients treated with HD for at least 6 months
Exclusion Criteria:
- Patients with malignancy and active inflammatory disease.
- Patients who received vitamin E or any antioxidant treatment during the past 3 months.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
omega-3 group
placebo group
Arm Description
omega-3 soft gelatin capsules 1000 mg (500mg EPA+250mg DHA)once daily for four months
empty soft gelatin capsules with matched size, color and shape once daily for four months
Outcomes
Primary Outcome Measures
effect on oxidative stress status via measurement of superoxide dismutase and glutathione peroxidase and malondialdehyde
Secondary Outcome Measures
effect on serum lipid levels (HDL cholesterol, LDL cholesterol, total cholesterol, and triglycerides)
Full Information
NCT ID
NCT02581449
First Posted
October 11, 2015
Last Updated
October 20, 2015
Sponsor
Ain Shams University
1. Study Identification
Unique Protocol Identification Number
NCT02581449
Brief Title
Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis
Official Title
Evaluation of the Effect of Omega-3 Fatty Acids Supplementation on Pediatric Patients Undergoing Hemodialysis
Study Type
Interventional
2. Study Status
Record Verification Date
October 2015
Overall Recruitment Status
Unknown status
Study Start Date
September 2015 (undefined)
Primary Completion Date
January 2016 (Anticipated)
Study Completion Date
January 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ain Shams University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of the study is to evaluate the effect of omega-3 fatty acids supplementation on pediatric patients undergoing hemodialysis via the measurement of the following before and after omega-3 administration:oxidative stress markers, inflammatory markers and serum lipids.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End Stage Renal Disease
Keywords
omega-3 fatty acids, hemodialysis, oxidative stress, dyslipidemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
omega-3 group
Arm Type
Experimental
Arm Description
omega-3 soft gelatin capsules 1000 mg (500mg EPA+250mg DHA)once daily for four months
Arm Title
placebo group
Arm Type
Placebo Comparator
Arm Description
empty soft gelatin capsules with matched size, color and shape once daily for four months
Intervention Type
Dietary Supplement
Intervention Name(s)
omega-3
Other Intervention Name(s)
NOW foods omega-3 softgels
Intervention Description
dietary supplement
Intervention Type
Other
Intervention Name(s)
empty soft gelatin capsules
Intervention Description
empty softgels of matched size, shape and color
Primary Outcome Measure Information:
Title
effect on oxidative stress status via measurement of superoxide dismutase and glutathione peroxidase and malondialdehyde
Time Frame
four months
Secondary Outcome Measure Information:
Title
effect on serum lipid levels (HDL cholesterol, LDL cholesterol, total cholesterol, and triglycerides)
Time Frame
four months
Other Pre-specified Outcome Measures:
Title
effect on inflammation via measurement of C- Reactive Protein
Time Frame
four months
Title
effect on nitric oxide (serum concentration)
Time Frame
four months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients between 8 and 18 years old
Patients treated with HD for at least 6 months
Exclusion Criteria:
Patients with malignancy and active inflammatory disease.
Patients who received vitamin E or any antioxidant treatment during the past 3 months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ain Shams
Organizational Affiliation
university
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis
We'll reach out to this number within 24 hrs